广州丙肝治疗医院丙肝治疗.pptVIP

* * Slide 27. Study designs: summary The study by Berg and colleagues compared treatment of genotype 1 patients randomised at baseline to receive PEGASYS? 180 μg/wk plus COPEGUS? 800 mg/day for 48 weeks (n=230) versus 72 weeks (n=225).1 The study by Sánchez-Tapias et al involved 510 patients treated with PEGASYS? 180 μg/wk plus COPEGUS? 800 mg/day. The 326 patients who did not achieve an RVR at week 4 were randomized to receive 48 weeks or (n=165) or 72 weeks (n=161) of treatment.2 Those patients who achieved an RVR were randomised to receive 24 or 48 weeks’ treatment, depending on genotype